Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

por Ouerdani, A, Struemper, H, Suttle, AB, Ouellet, D, Ribba, B
Publicado 2015

Time-Course Analysis of Main Markers of Primary Infection in Cats with the Feline Immunodeficiency Virus

por Ribba, B., El Garch, H., Brunet, S., Grenier, E., Castiglione, F., Poulet, H., Vanhems, P.
Publicado 2012

Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs

por Hutchinson, LG, Mueller, H‐J, Gaffney, EA, Maini, PK, Wagg, J, Phipps, A, Boetsch, C, Byrne, HM, Ribba, B
Publicado 2016

Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation

por Ribba, B, Grimm, HP, Agoram, B, Davies, MR, Gadkar, K, Niederer, S, van Riel, N, Timmis, J, van der Graaf, PH
Publicado 2017

A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis

por Ribba, B, Holford, N H, Magni, P, Trocóniz, I, Gueorguieva, I, Girard, P, Sarr, C, Elishmereni, M, Kloft, C, Friberg, L E
Publicado 2014

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings

por Wilson, S, Tod, M, Ouerdani, A, Emde, A, Yarden, Y, Adda Berkane, A, Kassour, S, Wei, MX, Freyer, G, You, B, Grenier, E, Ribba, B
Publicado 2015

Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue

por Stroh, M, Carlile, DJ, Li, C-C, Wagg, J, Ribba, B, Ramanujan, S, Jin, J, Xu, J, Charoin, J-E, Xhu, Z-X, Morcos, PN, Davis, JD, Phipps, A
Publicado 2015

Prediction of Response to Temozolomide in Low‐Grade Glioma Patients Based on Tumor Size Dynamics and Genetic Characteristics

por Mazzocco, P, Barthélémy, C, Kaloshi, G, Lavielle, M, Ricard, D, Idbaih, A, Psimaras, D, Renard, M‐A, Alentorn, A, Honnorat, J, Delattre, J‐Y, Ducray, F, Ribba, B
Publicado 2015

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

por Swat, MJ, Moodie, S, Wimalaratne, SM, Kristensen, NR, Lavielle, M, Mari, A, Magni, P, Smith, MK, Bizzotto, R, Pasotti, L, Mezzalana, E, Comets, E, Sarr, C, Terranova, N, Blaudez, E, Chan, P, Chard, J, Chatel, K, Chenel, M, Edwards, D, Franklin, C, Giorgino, T, Glont, M, Girard, P, Grenon, P, Harling, K, Hooker, AC, Kaye, R, Keizer, R, Kloft, C, Kok, JN, Kokash, N, Laibe, C, Laveille, C, Lestini, G, Mentré, F, Munafo, A, Nordgren, R, Nyberg, HB, Parra-Guillen, ZP, Plan, E, Ribba, B, Smith, G, Trocóniz, IF, Yvon, F, Milligan, PA, Harnisch, L, Karlsson, M, Hermjakob, H, Le Novère, N
Publicado 2015